Psyence BioMed Secures U.S. Manufacturing Deal for Pharmaceutical-Grade Ibogaine
Event summary
- Psyence BioMed's subsidiary, Texas Ibogaine Research Corporation (TIRC), partners with Benuvia Operations for U.S. manufacturing of pharmaceutical-grade ibogaine API under cGMP standards.
- Benuvia's 83,000-square-foot DEA-registered facility in Round Rock, Texas, will handle development through commercial-scale production.
- The partnership aims to establish an end-to-end U.S. supply and manufacturing pathway for ibogaine, pending DEA quota expansions and regulatory authorizations.
- TIRC has a binding term sheet with PsyLabs for exclusive U.S. license, supply, and wholesale distribution of pharmaceutical-grade ibogaine, with a definitive agreement expected by November 30, 2026.
The big picture
This partnership marks a strategic move to vertically integrate ibogaine production in the U.S., aligning with broader industry trends toward controlled-substance manufacturing for mental health applications. The deal positions Psyence BioMed to support future clinical programs, though success hinges on navigating stringent DEA regulations and securing expanded production quotas. The collaboration with Benuvia provides a critical infrastructure advantage, but the path to commercial-scale manufacturing remains contingent on regulatory milestones.
What we're watching
- Regulatory Approvals
- The pace at which the DEA processes import permits and procurement quotas will determine the timeline for U.S. ibogaine production.
- Supply Chain Control
- Whether TIRC can sustain a reliable supply chain given its reliance on a single manufacturing partner and a related-party supplier.
- Market Expansion
- How potential DEA quota expansions could impact the scale and commercial viability of ibogaine-based therapies.
